Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2005-07-12
2011-10-11
Canella, Karen (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
C424S572000, C424S573000
Reexamination Certificate
active
08034360
ABSTRACT:
The invention here relates to a product comprised of a cell line or lines intended for use as an allogeneic immunotherapy agent for the treatment of cancer in mammals and humans. All of the studies of cell-based cancer vaccines to date have one feature in common, namely the intention to use cells that contain at least some TSAs and/or TAAs that are shared with the antigens present in patients' tumor. In each case, tumor cells are utilized as the starting point on the premise that only tumor cells will contain TSAs or TAAs of relevance, and the tissue origins of the cells are matched to the tumor site in patients. A primary aspect of the invention is the use of immortalized normal, non-malignant cells as the basis of an allogeneic cell cancer vaccine. Normal cells do not possess TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines. For prostate cancer, for example, a vaccine may be based on one or a combination of different immortalized normal cell lines derived from the prostate. The cell lines are lethally irradiated utilizing gamma irradiation at 50-300 Gy to ensure that they are replication incompetent prior to use in the mammal or human.
REFERENCES:
patent: 6207805 (2001-03-01), Weiner et al.
patent: 6972128 (2005-12-01), Dalgleish et al.
patent: WO95/29704 (1995-11-01), None
patent: WO97/28255 (1997-08-01), None
Bodey B et al. Anticancer Research 20: 2665-2676, 2000.
Paul, Fundamental Immunology, (text), 1993, pp. 1157-1170.
Finke et al, Immunology Today, 1999, vol. 20, pp. 158-160.
Antoinia et al (International Immunology, 1995, vol. 7, pp. 715-725).
Lee et al (Journal of Immunology, 1999, vol. 163, pp. 6292-6300).
Nielsen et al (Cancer Chemother Pharmacol, 2000, vol. 46 (suppl), pp. S62-S66).
Yu and Restifo (Journal of Clinical Investigation, 2002, vol. 110, pp. 289-294).
Agus et al (Cancer Research, 1999, vol. 59, pp. 4761-4764).
Clark (Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, 1993, pp. 4-5).
Abstract of Wheeler (Salud p'ublica de M'exico, (Jul.-Aug. 1997) 39 (4) 283-7).
Efferson et al (Anticancer research, 2005, vol. 25, pp. 715-724).
Bachman et al (Journal of Immunology, 2005, vol. 175, pp. 4677-4685).
Rokhlin et al (Cancer Letters, 1995, vol. 98, pp. 103-110).
Maurer and Callahan, Methods in Enzymology, 1980, vol. 70A, pp. 49-70).
Tabstract of Abbas et al, Seminars in Immunology, 1993, vol. 5, pp. 441-447.
Ablin, J. Cancer Res. Clin. Oncol. 123: 583-594 (1997).
Berthon et al., Intl. J. Oncology 6(2): 333-343 (1995).
Brenner et al., Journal of Urology, pp. 1575-1579 (1995) (abstract only).
Curti, Crit. Rev. in Oncology/Hematology 14: 29-39 (1993).
Dermer, Bio/Technology 12: 320 (1994).
Drexler et al., Leukemia and Lymphoma 9: 1-25 (1993).
Embleton et al., Immunol. Ser. 23: 181-207 (1984).
Freshney, Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., NY (1983).
Gorelik et al., Journal of Supramolecular Structure 12: 385-402 (1979) (abstract only).
Gura, Science 278: 1041-1042 (1997).
Hartwell et al., Science 278: 1064-1068 (1997).
Hsu, Tissue Culture Methods and Applications, Kruse and Patterson, Eds, Academic Press, NY (1973).
Jain, Sci. Am. 271: 58-65 (1994).
Marble, Cancer Weekly Plus, p. 4(2) (1997).
Moran, American Medical News 42, 39, 23 (1999).
Tjoa et al., The Prostate 27: 63-69 (1995).
Triest et al., Clinical Cancer Res. 4(8): 2009-2014 (1998).
Vieweg et al., Cancer Research 54: 1760-1765 (1994).
Wu et al., Intl. J. Cancer 77(6): 887-894 (1998).
Dalgleish Angus George
Smith Peter Michael
Sutton Andrew Derek
Walker Anthony Ian
Canella Karen
Onyvax Limited
Perkins Coie LLP
LandOfFree
Use of human prostate cell lines in cancer treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of human prostate cell lines in cancer treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of human prostate cell lines in cancer treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4291023